Swiss Vaccine Center

Swiss Vaccine Center
Name	Swiss Vaccine Center
Formation	2017
Headquarters	Lausanne, Canton of Vaud
Region served	Switzerland, Europe, Global
Leader title	Director

Swiss Vaccine Center is a translational vaccinology institute based in Lausanne, Canton of Vaud. It functions as a collaborative node linking École polytechnique fédérale de Lausanne, University of Lausanne, University Hospital of Lausanne, and other European and international research institutions. The center focuses on vaccine design, preclinical testing, and early-phase clinical development to address infectious diseases and immunological disorders.

Overview

The center integrates expertise from École polytechnique fédérale de Lausanne, University of Lausanne, University Hospital of Lausanne, Paul Scherrer Institute, Swiss Federal Institute of Technology, Swiss Tropical and Public Health Institute, and international partners such as World Health Organization, European Commission, Bill & Melinda Gates Foundation, and Coalition for Epidemic Preparedness Innovations to accelerate vaccine pipelines. Its mission aligns with national initiatives including Swiss National Science Foundation programs and European Research Council-funded projects while engaging with regulatory agencies like Swissmedic and European Medicines Agency.

History and Establishment

The initiative emerged from collaborative discussions among leaders at École polytechnique fédérale de Lausanne, University of Lausanne, and clinicians at University Hospital of Lausanne following global outbreaks such as the 2014 Ebola epidemic and the 2015–2016 Zika virus epidemic. Seed funding was provided by cantonal authorities in Canton of Vaud and philanthropies including Fondation Botnar and private donors linked to Novartis alumni. Launch events involved representatives from Federal Department of Home Affairs (Switzerland), Swiss Academy of Medical Sciences, and partners from Institut Pasteur and Karolinska Institutet.

Research and Development

Research programs span antigen discovery, adjuvant development, nanoparticle delivery, and immunomonitoring, drawing on methods from groups at École polytechnique fédérale de Lausanne and the Paul Scherrer Institute synchrotron for structural biology. Projects have investigated pathogens such as influenza virus, SARS-CoV-2, Zika virus, Dengue virus, and Mycobacterium tuberculosis while collaborating with immunology teams at Imperial College London, Massachusetts Institute of Technology, Harvard Medical School, and University of Oxford. Basic science integrates input from labs formerly associated with Novartis Institutes for BioMedical Research and biotechnology firms like Roche and Lonza on upstream process development.

Clinical Trials and Vaccine Programs

The center coordinates early-phase trials in collaboration with University Hospital of Lausanne clinical units, using trial networks such as Swiss Clinical Trial Organisation, EQUATOR Network, and partnerships with ClinicalTrials.gov-registered consortia. It has been involved in Phase I and Phase II studies for candidates against SARS-CoV-2 and seasonal influenza, working with contract research organizations including Parexel and PRA Health Sciences, and regulatory consultation with Swissmedic and European Medicines Agency experts. Trial cohorts have drawn participants via links to Cantonal hospitals of Switzerland and community outreach with organizations like Médecins Sans Frontières.

Partnerships and Collaborations

Formal collaborations include agreements with École polytechnique fédérale de Lausanne, University of Lausanne, University Hospital of Lausanne, Paul Scherrer Institute, Institut Pasteur, Karolinska Institutet, Imperial College London, University of Oxford, Harvard Medical School, Massachusetts Institute of Technology, Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, and industry partners such as Novartis, Roche, and Lonza. It participates in European consortia funded by the Horizon 2020 and Horizon Europe programs, collaborating with networks like European Vaccine Initiative and Vaccine Task Force members.

Infrastructure and Facilities

Facilities include Good Manufacturing Practice suites for investigational vaccine production aligned with standards from Swissmedic and European Medicines Agency, high-containment laboratories modeled on protocols from World Health Organization, immunology core platforms shared with University of Lausanne, and structural biology resources in partnership with Paul Scherrer Institute and synchrotron beamlines. Data infrastructure leverages bioinformatics collaborations with Swiss Institute of Bioinformatics and high-performance computing provided through École polytechnique fédérale de Lausanne.

Governance and Funding

Governance is overseen by a board composed of representatives from École polytechnique fédérale de Lausanne, University of Lausanne, University Hospital of Lausanne, cantonal authorities of Canton of Vaud, and external scientific advisors from institutions such as Karolinska Institutet and Imperial College London. Funding streams combine grants from the Swiss National Science Foundation, philanthropic grants from Fondation Botnar and Bill & Melinda Gates Foundation, European funding via Horizon Europe, and industry-sponsored research agreements with partners including Novartis, Roche, and Lonza.

Impact and Public Health Contributions

The center has contributed to translational projects that informed pandemic responses to SARS-CoV-2 and provided platforms for accelerated vaccine candidate evaluation used by partners like Coalition for Epidemic Preparedness Innovations and World Health Organization advisory bodies. Its collaborations with University Hospital of Lausanne, Cantonal hospitals of Switzerland, Swiss Tropical and Public Health Institute, and international partners have supported capacity building for clinical trials, cold-chain logistics, and immunosurveillance linked to surveillance networks such as European Centre for Disease Prevention and Control-aligned initiatives.

Category:Medical research institutes in Switzerland